arrow
S

Serkan Özakbaş

Izmir University of Economics
H指数:30
被引数:3,471

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How patients with neuromyelitis optica spectrum disease accumulate disability

视神经脊髓炎谱系疾病患者如何累积残疾

2026-10-080
PRE
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

在复发缓解型多发性硬化中,针对临床静息期MRI病灶的治疗升级

Brain
IF11.7
2026-07-240
OAAI
Causal effects of multiple sclerosis therapies in left-truncated registry data

多发性硬化疗法在左截断登记数据中的因果效应

2026-07-210
PRE
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry

抗CD20疗法与S1P受体调节剂在迟发性多发性硬化中的比较疗效:来自MSBase注册研究的真实世界证据

2026-03-260
PRE
Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: an MSBase Registry Sub-Study

奥法美南在复发型多发性硬化中的真实世界有效性:一项MSBase登记研究的子研究

2025-11-250
OAAI
Disease course after pregnancy in women with progressive multiple sclerosis symptoms

妊娠后进展性多发性硬化症状女性的疾病病程

2025-09-200
OA
Prevalence and magnitude of perceived dual-task difficulties in people with multiple sclerosis: an international study

多发性硬化患者感知双重任务困难的患病率及严重程度:一项国际研究

2025-09-060
PRE
Persistent progression independent of relapse activity in multiple sclerosis

多发性硬化中与复发活动无关的持续性进展

2025-08-210
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

基于真实世界常规临床数据的个性化联邦学习在预测多发性硬化致残进展中的应用

2025-07-240
OAAI
Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)

利妥昔单抗与硫唑嘌呤在治疗MOG抗体相关疾病(MOGAD)中的比较疗效

2025-07-090
PRE
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE